Patents by Inventor Kandaswamy Sumathy
Kandaswamy Sumathy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11406698Abstract: The present disclosure provides vaccine compositions for prophylaxis and treatment of Zika virus infections comprising Zika virus antigens in immunogenic compositions, and in combination of Zika antigens with one or more arbovirus antigens such as Chikungunya virus and Japanese encephalitis virus antigens, methods of preparation and production of such compositions for use as vaccines for eliciting immune response in mammals against the above mentioned pathogens.Type: GrantFiled: March 8, 2020Date of Patent: August 9, 2022Assignee: Bharat Biotech International LimitedInventors: Kandaswamy Sumathy, Krishna Murthy Ella
-
Publication number: 20210187093Abstract: The present disclosure provides vaccine compositions for prophylaxis and treatment of Zika virus infections comprising Zika virus antigens in immunogenic compositions, and in combination of Zika antigens with one or more arbovirus antigens such as Chikungunya virus and Japanese encephalitis virus antigens, methods of preparation and production of such compositions for use as vaccines for eliciting immune response in mammals against the above mentioned pathogens.Type: ApplicationFiled: March 8, 2020Publication date: June 24, 2021Applicant: Bharat Biotech International LimitedInventors: Kandaswamy Sumathy, Krishna Murthy Ella
-
Patent number: 10588956Abstract: The present disclosure provides vaccine compositions for prophylaxis and treatment of Zika virus infections comprising Zika virus antigens in immunogenic compositions, and in combination of Zika antigens with one or more arbovirus antigens such as Chikungunya virus and Japanese encephalitis virus antigens, methods of preparation and production of such compositions for use as vaccines for eliciting immune response in mammals against the above mentioned pathogens.Type: GrantFiled: July 18, 2016Date of Patent: March 17, 2020Assignee: Bharat Biotech International LimitedInventors: Kandaswamy Sumathy, Krishna Murthy Ella
-
Patent number: 10058605Abstract: Vaccine combinations which comprise at least two or more of the following antigens: DTap-HEV-HepB-HPV suitable for administration in humans. A number of variations in the combination of these antigens have been disclosed that is suitable for concomitant administration. The methods of preparing the vaccine combinations are disclosed. Nucleic acids encoding the antigens, as well as methods for their production and use are provided.Type: GrantFiled: May 9, 2013Date of Patent: August 28, 2018Assignee: Bharat Biotech International LimitedInventors: Krishna Murthy Ella, Kandaswamy Sumathy
-
Publication number: 20170014502Abstract: The present disclosure provides vaccine compositions for prophylaxis and treatment of Zika virus infections comprising Zika virus antigens in immunogenic compositions, and in combination of Zika antigens with one or more arbovirus antigens such as Chikungunya virus and Japanese encephalitis virus antigens, methods of preparation and production of such compositions for use as vaccines for eliciting immune response in mammals against the above mentioned pathogens.Type: ApplicationFiled: July 18, 2016Publication date: January 19, 2017Inventors: Kandaswamy SUMATHY, Krishna Murthy Ella
-
Publication number: 20160015804Abstract: Vaccine combinations which comprise at least two or more of the following antigens: DTap-HEV-HepB-HPV suitable for administration in humans. A number of variations in the combination of these antigens have been disclosed that is suitable for concomitant administration. The methods of preparing the vaccine combinations are disclosed. Nucleic acids encoding the antigens, as well as methods for their production and use are provided.Type: ApplicationFiled: May 9, 2013Publication date: January 21, 2016Inventors: Krishna Murthy ELLA, Kandaswamy SUMATHY
-
Patent number: 8968728Abstract: New thrombolytic protein molecules such as recombinant staphylokinase or streptokinase, urokinase, tissue plasminogen activator and the like, and suitable variants thereof, for targeting to brain tissue or any other tissue by either fusing to, or by synthesizing the candidate thrombolytic molecule(s) with a protein sequence comprising a strong amphipathic alpha helix containing protein transduction domain. Thrombolytic protein molecule(s) so engineered with the protein transduction domain is useful for enhanced uptake of such protein thrombolytic molecule(s) across the cell membranes and tissues including the blood brain barrier and find their use in the treatment of vascular thrombosis including cerebrovascular disorders caused by cerebral thrombosis or cerebral haemorrhage when used a as a therapeutic. The design and processes for cloning, expression, purification and protein transduction of such proteins across cell membranes.Type: GrantFiled: May 11, 2007Date of Patent: March 3, 2015Assignee: Bharat Biotech International LimitedInventors: Krishna Murthy Ella, Kandaswamy Sumathy
-
Patent number: 8865184Abstract: The present invention relates to vaccine formulation capable of eliciting protective immune response against Chikungunya virus infection in humans and other mammalian hosts. The immunogenic formulation comprises purified inactivated Chikungunya virus in a stable formulation. Methods of propagation and purification of the virus are discussed. The inactivated virus formulation is non-infectious, immunogenic and elicits protective immune response in mammalian host. The immunogenic composition is formulated for in vivo administration to humans. The invention also discusses the strategy of developing a subunit vaccine using the recombinant viral proteins as antigens for immunization. The recombinant virus antigens that are potentially immunogenic can be used in diagnosing for the presence of the virus.Type: GrantFiled: August 31, 2007Date of Patent: October 21, 2014Assignee: Bharat Biotech International LimitedInventors: Murthy Krishna Ella, Kandaswamy Sumathy, Jaya Sheela Pydigummala, Nagendra R. Hegde
-
Publication number: 20130022631Abstract: The present invention relates to vaccine formulation capable of eliciting protective immune response against Chikun-gunya virus infection in humans and other mammalian hosts. The immunogenic formulation comprises purified inactivated Chikun-gunya virus in a stable formulation. Methods of propagation and purification of the virus are discussed. The inactivated virus formulation is non-infectious, immunogenic and elicits protective immune response in mammalian host. The immunogenic composition is formulated for in vivo administration to humans. The invention also discusses the strategy of developing a subunit vaccine using the recombinant viral proteins as antigens for immunization. The recombinant virus antigens that are potentially immunogenic can be used in diagnosing for the presence of the virus.Type: ApplicationFiled: August 31, 2007Publication date: January 24, 2013Inventors: Krishna Murthy Ella, Kandaswamy Sumathy, Jaya Sheela Pydigummala, Nagendra R. Hedge
-
Publication number: 20100173842Abstract: The invention relates to a method of preparation and use of a polypeptide vaccine formulation for prevention and control of Staphylococci mediated infections in human, bovine and other mammals, using recombinant DNA technology.Type: ApplicationFiled: October 8, 2009Publication date: July 8, 2010Applicant: BHARAT BIOTECH INTERNATIONAL LIMITEDInventors: Krishna Murthy ELLA, Kandaswamy SUMATHY, Krishna Mohan VADREVU
-
Publication number: 20100015123Abstract: New thrombolytic protein molecules such as recombinant staphylokinase or streptokinase, urokinase, tissue plasminogen activator and the like, and suitable variants thereof, for targeting to brain tissue or any other tissue by either fusing to, or by synthesizing the candidate thrombolytic molecule(s) with a protein sequence comprising a strong amphipathic alpha helix containing protein transduction domain. Thrombolytic protein molecule(s) so engineered with the protein transduction domain is useful for enhanced uptake of such protein thrombolytic molecule(s) across the cell membranes and tissues including the blood brain barrier and find their use in the treatment of vascular thrombosis including cerebrovascular disorders caused by cerebral thrombosis or cerebral haemorrhage when used a as a therapeutic. The design and processes for cloning, expression, purification and protein transduction of such proteins across cell membranes.Type: ApplicationFiled: May 11, 2007Publication date: January 21, 2010Applicant: BHARAT BIOTECH INTERNATIONAL LIMITEDInventors: Krishna Murthy Ella, Kandaswamy Sumathy
-
Publication number: 20090220538Abstract: The present invention describes method of preparation and use of polypeptide vaccine formulation for prevention and control of Staphylococci mediated infections in human, bovine and other mammals, using recombinant DNA technology.Type: ApplicationFiled: July 13, 2006Publication date: September 3, 2009Applicant: BHARAT BIOTECH INTERNATIONAL LIMITEDInventors: Krishna Murthy Ella, Kandaswamy Sumathy, Krishna Mohan Vadrevu